State Street’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22M | Buy |
7,145,550
+2,025,847
| +40% | +$8.6M | ﹤0.01% | 2199 |
|
|
2025
Q4 | $18.5M | Buy |
5,119,703
+1,518,448
| +42% | +$6.62M | ﹤0.01% | 2311 |
|
|
2025
Q3 | $13.6M | Buy |
3,601,255
+847,617
| +31% | +$3.27M | ﹤0.01% | 2450 |
|
|
2025
Q2 | $10.7M | Sell |
2,753,638
-637,933
| -19% | -$3.45M | ﹤0.01% | 2563 |
|
|
2025
Q1 | $17M | Sell |
3,391,571
-78,446
| -2% | -$497K | ﹤0.01% | 2228 |
|
|
2024
Q4 | $25M | Buy |
3,470,017
+56,190
| +2% | +$429K | ﹤0.01% | 2099 |
|
|
2024
Q3 | $21M | Sell |
3,413,827
-495,459
| -13% | -$3.36M | ﹤0.01% | 2175 |
|
|
2024
Q2 | $26M | Sell |
3,909,286
-4,739,984
| -55% | -$35M | ﹤0.01% | 2037 |
|
|
2024
Q1 | $88M | Buy |
8,649,270
+7,634,724
| +753% | +$77.7M | ﹤0.01% | 1395 |
|
|
2023
Q4 | $11.4M | Buy |
1,014,546
+143,665
| +16% | +$600K | ﹤0.01% | 2519 |
|
|
2023
Q3 | $2.26M | Buy |
870,881
+66,808
| +8% | +$192K | ﹤0.01% | 3273 |
|
|
2023
Q2 | $2.84M | Sell |
804,073
-4,155,181
| -84% | -$18.7M | ﹤0.01% | 3252 |
|
|
2023
Q1 | $20.9M | Sell |
4,959,254
-955,334
| -16% | -$11.3M | ﹤0.01% | 2194 |
|
|
2022
Q4 | $97.3M | Buy |
5,914,588
+2,515,732
| +74% | +$28.3M | 0.01% | 1176 |
|
|
2022
Q3 | $43.4M | Buy |
3,398,856
+3,263,310
| +2,408% | +$48.2M | ﹤0.01% | 1688 |
|
|
2022
Q2 | $1.59M | Sell |
135,546
-555,595
| -80% | -$3.43M | ﹤0.01% | 3528 |
|
|
2022
Q1 | $4.21M | Sell |
691,141
-3,730,400
| -84% | -$27.5M | ﹤0.01% | 3269 |
|
|
2021
Q4 | $40.5M | Buy |
4,421,541
+897,523
| +25% | +$9.54M | ﹤0.01% | 1952 |
|
|
2021
Q3 | $39.9M | Sell |
3,524,018
-159,298
| -4% | -$1.94M | ﹤0.01% | 1981 |
|
|
2021
Q2 | $36.3M | Buy |
3,683,316
+741,137
| +25% | +$10.1M | ﹤0.01% | 2085 |
|
|
2021
Q1 | $41.6M | Buy |
+2,942,179
| New | +$47.6M | ﹤0.01% | 1882 |
|
|
2017
Q2 | – | Sell |
-3,030
| Closed | -$738K | – | 3701 |
|
|
2017
Q1 | $738K | Sell |
3,030
-60
| -2% | -$32.1K | ﹤0.01% | 3335 |
|
|
2016
Q4 | $3.01M | Buy |
3,090
+544
| +21% | +$487K | ﹤0.01% | 2934 |
|
|
2016
Q3 | $2.22M | Buy |
2,546
+598
| +31% | +$469K | ﹤0.01% | 2933 |
|
|
2016
Q2 | $1.43M | Buy |
1,948
+1,892
| +3,379% | +$1.29M | ﹤0.01% | 3165 |
|
|
2016
Q1 | $32K | Hold |
56
| – | – | ﹤0.01% | 3641 |
|
|
2015
Q4 | $32K | Hold |
56
| – | – | ﹤0.01% | 3627 |
|
|
2015
Q3 | $22K | Hold |
56
| – | – | ﹤0.01% | 3649 |
|
|
2015
Q2 | $31K | Hold |
56
| – | – | ﹤0.01% | 3636 |
|
|
2015
Q1 | $26K | Hold |
56
| – | – | ﹤0.01% | 3624 |
|
|
2014
Q4 | $31K | Sell |
56
-6
| -10% | -$3.08K | ﹤0.01% | 3623 |
|
|
2014
Q3 | $34K | Hold |
62
| – | – | ﹤0.01% | 3606 |
|
|
2014
Q2 | $26K | Hold |
62
| – | – | ﹤0.01% | 3593 |
|
|
2014
Q1 | $34K | Hold |
62
| – | – | ﹤0.01% | 3584 |
|
|
2013
Q4 | $35K | Hold |
62
| – | – | ﹤0.01% | 3560 |
|
|
2013
Q3 | $39K | Hold |
62
| – | – | ﹤0.01% | 3546 |
|
|
2013
Q2 | $29K | Buy |
+62
| New | +$30.7K | ﹤0.01% | 3493 |
|
Other funds holding ALT
VCM
VPM
N
State Street's ALT Position: Q1 2026 in Review
State Street increased its Altimmune (ALT) stake by 40% in Q1 2026, buying an estimated $8.6M and bringing the position to 7,145,550 shares worth $22M. The position accounts for ﹤0.01% of the portfolio, ranked #2199.
State Street first reported a position in ALT in Q2 2013 and has held it in 37 quarters since. The position peaked at $97.3M in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- State Street held 7,145,550 shares of Altimmune worth $22M as of Q1 2026.
- State Street bought 2,025,847 Altimmune shares in Q1 2026, an estimated $8.6M.
- Altimmune made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2199 holding.
- State Street first reported a position in Altimmune in Q2 2013 and has held it in 37 quarters since.
- State Street's Altimmune position peaked at $97.3M in Q4 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.